Skip to main content
The NCI Community Hub will be retiring in May 2024. For more information please visit the NCIHub Retirement Page:https://ncihub.cancer.gov/groups/ncihubshutdown/overview
close

NCL Method ITA-35

By Enping Hong, Marina Dobrovolskaia

Antigen-Specific Stimulation of CD8+ T-cells by Murine Bone Marrow-Derived Dendritic Cells

Listed in Datasets | publication by group NCL Protocols

Version 1.0 - published on 04 May 2020 doi:10.17917/1QRB-NC62 - cite this

Licensed under these terms

Description

The stimulation of antigen-specific T-cell responses is critical for therapeutic cancer vaccines. Extensive efforts have been made to develop nanoparticles as carriers of therapeutic cancer vaccines to antigen presenting cells (APCs) of the immune system. The purpose of this protocol is to use nanoparticles to deliver vaccines to APCs and measure the antigen-specific T-cell responses that are instigated. For the purposes of this assay, the model antigen ovalbumin (OVA) is used in the context of murine cells. The protocol requires the synthesis of nanoparticles that deliver SIINFEKL (OVA257-264), the immunodominant class I peptide derived from OVA, either in its peptide form or as part of a larger molecule (such as the whole OVA protein). CD8+ T-cells that recognize SIINFEKL are purified from the transgenic OT-I mouse model [1], and activated using nanoparticle-treated APCs. The resulting T-cell proliferation, as well as secretion of the cytokines interferon gamma (IFN-g) and interleukin-2 (IL-2), are used to measure antigen-specific T-cell activation. The results of this protocol may be used to infer the ability of the nanoparticle system to deliver other similar antigens.

Content List

Cite this work

Researchers should cite this work as follows:

Tags

Recommendations

Powered by ...

NCL Protocols

NCL Protocols group image

When watching a publication, you will be notified when a new version is released.